Dr Reddy’s Global Strides — Will the Success Story Continue?

Lekha Ravi

Chapter 8 in India: Acquiring its Way to a Global Footprint, 2012, pp 91-102 from Palgrave Macmillan

Abstract: Abstract In February 2006, Dr Reddy’s Laboratories Limited (DRL) acquired the fourth largest generic pharmaceutical company in Germany, Betapharm Arzneimittel GmbH (Betapharm) from the 3i Group PLC (3i) paying US $570 million (€480 million). This acquisition was funded through a combination of internal accruals and borrowings. Immediately after the deal, health care reforms took place in Germany setting lower reference prices for drugs, forcing companies to cut prices. Many analysts felt that DRL had paid too much for the acquisition as the valuation of the deal was approximated to be more than thrice the annual sales of Betapharm. Would DRL be able to prove the critics wrong and realise their ambition of becoming a US $1 billion mid-size global pharmaceutical company by 2008?

Keywords: Generic Drug; Health Care Reform; Corporate Social Responsibility Enterprise; Indian Market; Generic Market (search for similar items in EconPapers)
Date: 2012
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-36353-3_8

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230363533

DOI: 10.1057/9780230363533_8

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().